Which has preferable earnings & valuation, TIL or IMUX?

Immunic is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$7.08 N/A Immunic N/A N/A -$97.17M -$5.58 N/A

Is TIL or IMUX more profitable?

Instil Bio's return on equity of -39.76% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -39.76% -22.38% Immunic N/A -220.75% -132.04%

Is KRRO or TIL more profitable?

Instil Bio has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Instil Bio's return on equity of -39.76% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Korro Bio -1,834.48% -117.86% -71.04% Instil Bio N/A -39.76% -22.38%

Which has preferable valuation and earnings, NKTX or TIL?

Nkarta is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nkarta N/A N/A -$104.08M -$1.34 N/A Instil Bio N/A N/A -$71.37M -$7.08 N/A

Is NKTX or TIL more profitable?

Nkarta's return on equity of -30.90% beat Instil Bio's return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -30.90% -24.20% Instil Bio N/A -39.76% -22.38%

Instil Bio (TIL) Competitors

$7.68 -0.01 (-0.13%)

As of 02:44 PM Eastern

Compare

TIL vs. KPTI, IMUX, KRRO, NKTX, and PRQR

Should you buy Instil Bio stock or one of its competitors? MarketBeat compares Instil Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Instil Bio include Karyopharm Therapeutics (KPTI), Immunic (IMUX), Korro Bio (KRRO), Nkarta (NKTX), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry.

How does Instil Bio compare to Karyopharm Therapeutics?

Instil Bio (NASDAQ:TIL) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by company insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Instil Bio has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Instil Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

Instil Bio has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

In the previous week, Karyopharm Therapeutics had 1 more articles in the media than Instil Bio. MarketBeat recorded 2 mentions for Karyopharm Therapeutics and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.87 beat Karyopharm Therapeutics' score of 0.94 indicating that Instil Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Instil Bio	Very Positive
Karyopharm Therapeutics	Positive

Instil Bio presently has a consensus price target of $66.00, suggesting a potential upside of 759.38%. Karyopharm Therapeutics has a consensus price target of $17.17, suggesting a potential upside of 76.43%. Given Instil Bio's higher probable upside, equities analysts clearly believe Instil Bio is more favorable than Karyopharm Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Instil Bio has higher earnings, but lower revenue than Karyopharm Therapeutics. Instil Bio is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
Karyopharm Therapeutics	$146.07M	1.51	-$196.04M	-$15.09	N/A

Summary

Instil Bio and Karyopharm Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Instil Bio compare to Immunic?

Instil Bio (NASDAQ:TIL) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

In the previous week, Immunic had 3 more articles in the media than Instil Bio. MarketBeat recorded 4 mentions for Immunic and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.87 beat Immunic's score of 0.73 indicating that Instil Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Instil Bio	Very Positive
Immunic	Positive

Instil Bio's return on equity of -39.76% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
Immunic	N/A	-220.75%	-132.04%

Immunic is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

Instil Bio has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market. Comparatively, Immunic has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market.

Instil Bio presently has a consensus price target of $66.00, indicating a potential upside of 759.38%. Immunic has a consensus price target of $47.57, indicating a potential upside of 218.42%. Given Instil Bio's higher probable upside, equities research analysts clearly believe Instil Bio is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

60.6% of Instil Bio shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 47.0% of Instil Bio shares are held by company insiders. Comparatively, 5.5% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Instil Bio beats Immunic on 9 of the 14 factors compared between the two stocks.

How does Instil Bio compare to Korro Bio?

Korro Bio (NASDAQ:KRRO) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

Instil Bio has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Instil Bio's return on equity of -39.76% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-117.86%	-71.04%
Instil Bio	N/A	-39.76%	-22.38%

13.2% of Korro Bio shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 4.8% of Korro Bio shares are held by insiders. Comparatively, 47.0% of Instil Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Korro Bio has a beta of 3, meaning that its stock price is 200% more volatile than the broader market. Comparatively, Instil Bio has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market.

Instil Bio has lower revenue, but higher earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39M	30.44	-$117.26M	-$11.67	N/A
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A

In the previous week, Korro Bio had 7 more articles in the media than Instil Bio. MarketBeat recorded 8 mentions for Korro Bio and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.87 beat Korro Bio's score of -0.12 indicating that Instil Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Korro Bio	Neutral
Instil Bio	Very Positive

Korro Bio currently has a consensus target price of $16.71, indicating a potential upside of 23.90%. Instil Bio has a consensus target price of $66.00, indicating a potential upside of 759.38%. Given Instil Bio's higher possible upside, analysts plainly believe Instil Bio is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Instil Bio beats Korro Bio on 10 of the 16 factors compared between the two stocks.

How does Instil Bio compare to Nkarta?

Nkarta (NASDAQ:NKTX) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 60.6% of Instil Bio shares are owned by institutional investors. 9.8% of Nkarta shares are owned by company insiders. Comparatively, 47.0% of Instil Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Nkarta has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Instil Bio has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market.

In the previous week, Nkarta had 1 more articles in the media than Instil Bio. MarketBeat recorded 2 mentions for Nkarta and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.87 beat Nkarta's score of 0.94 indicating that Instil Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Nkarta	Positive
Instil Bio	Very Positive

Nkarta currently has a consensus target price of $10.75, suggesting a potential upside of 276.53%. Instil Bio has a consensus target price of $66.00, suggesting a potential upside of 759.38%. Given Instil Bio's higher probable upside, analysts clearly believe Instil Bio is more favorable than Nkarta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Nkarta is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A

Nkarta's return on equity of -30.90% beat Instil Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-30.90%	-24.20%
Instil Bio	N/A	-39.76%	-22.38%

Summary

Nkarta and Instil Bio tied by winning 7 of the 14 factors compared between the two stocks.

How does Instil Bio compare to ProQR Therapeutics?

Instil Bio (NASDAQ:TIL) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

In the previous week, ProQR Therapeutics had 7 more articles in the media than Instil Bio. MarketBeat recorded 8 mentions for ProQR Therapeutics and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.87 beat ProQR Therapeutics' score of 0.50 indicating that Instil Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Instil Bio	Very Positive
ProQR Therapeutics	Positive

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Instil Bio has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. Instil Bio's return on equity of -39.76% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
ProQR Therapeutics	-331.33%	-84.87%	-37.78%

Instil Bio has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.07, indicating that its share price is 93% less volatile than the broader market.

Instil Bio presently has a consensus price target of $66.00, suggesting a potential upside of 759.38%. ProQR Therapeutics has a consensus price target of $7.33, suggesting a potential upside of 313.15%. Given Instil Bio's higher possible upside, analysts clearly believe Instil Bio is more favorable than ProQR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

ProQR Therapeutics has higher revenue and earnings than Instil Bio. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
ProQR Therapeutics	$17.99M	10.40	-$47.73M	-$0.50	N/A

Summary

Instil Bio beats ProQR Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Instil Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TIL vs. The Competition

Export

Metric	Instil Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$52.08M	$3.64B	$6.78B	$12.59B
Dividend Yield	N/A	2.20%	2.66%	6.15%
P/E Ratio	-1.08	21.43	27.44	25.41
Price / Sales	N/A	341.02	582.70	119.35
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	0.46	8.66	10.93	6.64
Net Income	-$71.37M	$23.87M	$3.57B	$336.83M
7 Day Performance	0.52%	3.48%	2.68%	2.93%
1 Month Performance	-5.30%	3.48%	1.77%	0.54%
1 Year Performance	-64.98%	66.58%	35.99%	30.13%

Instil Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TIL Instil Bio	1.9563 of 5 stars	$7.68 -0.1%	$66.00 +759.4%	-63.1%	$52.08M	N/A	N/A	410	Positive News Gap Up
KPTI Karyopharm Therapeutics	2.2736 of 5 stars	$9.65 +7.2%	$17.17 +77.9%	+126.7%	$203.97M	$146.07M	N/A	380	High Trading Volume
IMUX Immunic	3.6444 of 5 stars	$15.07 +2.2%	$47.57 +215.7%	+120.4%	$200.92M	N/A	N/A	70	News Coverage
KRRO Korro Bio	2.3159 of 5 stars	$13.71 -1.4%	$16.71 +21.9%	+5.5%	$200.47M	$6.39M	N/A	70	Gap Down High Trading Volume
NKTX Nkarta	4.0328 of 5 stars	$3.03 +8.6%	$10.75 +254.8%	+70.5%	$199.61M	N/A	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TIL) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Instil Bio (TIL) Competitors

TIL vs. KPTI, IMUX, KRRO, NKTX, and PRQR

How does Instil Bio compare to Karyopharm Therapeutics?

Summary

How does Instil Bio compare to Immunic?

Summary

How does Instil Bio compare to Korro Bio?

Summary

How does Instil Bio compare to Nkarta?

Summary

How does Instil Bio compare to ProQR Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TIL vs. The Competition

Instil Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Instil Bio (TIL) Competitors

TIL vs. KPTI, IMUX, KRRO, NKTX, and PRQR

How does Instil Bio compare to Karyopharm Therapeutics?

Do institutionals and insiders hold more shares of TIL or KPTI?

Is TIL or KPTI more profitable?

Which has more volatility and risk, TIL or KPTI?

Does the media favor TIL or KPTI?

Do analysts rate TIL or KPTI?

Which has stronger earnings & valuation, TIL or KPTI?

Summary

How does Instil Bio compare to Immunic?

Does the media refer more to TIL or IMUX?

Is TIL or IMUX more profitable?

Which has preferable earnings & valuation, TIL or IMUX?

Which has more volatility and risk, TIL or IMUX?

Do analysts prefer TIL or IMUX?

Do institutionals and insiders believe in TIL or IMUX?

Summary

How does Instil Bio compare to Korro Bio?

Is KRRO or TIL more profitable?

Do insiders & institutionals hold more shares of KRRO or TIL?

Which has more risk & volatility, KRRO or TIL?

Which has better valuation & earnings, KRRO or TIL?

Does the media refer more to KRRO or TIL?

Do analysts recommend KRRO or TIL?

Summary

How does Instil Bio compare to Nkarta?

Do institutionals and insiders have more ownership in NKTX or TIL?

Which has more risk and volatility, NKTX or TIL?

Does the media prefer NKTX or TIL?

Do analysts recommend NKTX or TIL?

Which has preferable valuation and earnings, NKTX or TIL?

Is NKTX or TIL more profitable?

Summary

How does Instil Bio compare to ProQR Therapeutics?

Does the media favor TIL or PRQR?

Do insiders and institutionals have more ownership in TIL or PRQR?

Is TIL or PRQR more profitable?

Which has more volatility and risk, TIL or PRQR?

Do analysts recommend TIL or PRQR?

Which has preferable earnings and valuation, TIL or PRQR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TIL vs. The Competition

Instil Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools